Week In Review: Eddingpharm To Pay $375 Million For Two Lilly Antibiotics And A Suzhou Manufacturing Facility

Eddingpharm, a Hong Kong-headquartered China in-licensing company, agreed to pay $375 million to acquire China rights for two off-patent antibiotics from Lilly and the Suzhou factory that makes the antibiotics.